01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan #ORPH – Additional Laboratory Services Contracts Signed with NOBACZ & Nearmedic International July 7, 2020 – Posted in: Open Orphan (ORPH)

7 July 2020 Open Orphan plc (“Open Orphan” or the “Company”) Additional Laboratory Services Contracts Signed   Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that as part of opening up its hVIVO laboratory services to third parties that it has signed 3 new contracts with third parties; NoBACZ Ltd…

Continue reading

Irish Independent – Open Orphan subsidiary starts testing drug for treating Covid-19 April 24, 2020 – Posted in: Open Orphan (ORPH)

by Ellie Donnelly A subsidiary of Open Orphan has started testing a drug that could potentially treat Covid-19. Open Orphan is a Europe- focused pharma services company specialising in rare disease and so-called orphan drugs. The tests are being carried out by its London-based subsidiary Hvivo on behalf of its client Nearmedic International. The drug being tested has both potential anti-viral and anti-inflammatory activity, and therefore could reduce both virus infectivity and disease severity respectively,…

Continue reading

Open Orphan #ORPH – Testing of anti-viral for treating COVID-19 underway April 23, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that its London-based subsidiary hVIVO has commenced the testing of an anti-viral for treating COVID-19 on behalf of its client Nearmedic International Ltd. hVIVO has initiated work on this contract with Nearmedic International Ltd, a specialist pharmaceutical, biotechnological…

Continue reading